Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract provides a comprehensive overview of enzyme classification, function, and interaction with drugs, but does not present new research findings.

Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.

This review explored the new and emerging treatments for androgenetic alopecia and alopecia areata, finding that JAK inhibitors show promise for alopecia areata, while advancements in stem-cell research may eventually lead to new and improved treatments for androgenetic alopecia.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This article poses the question of whether Janus kinase (JAK) inhibitors are beneficial for treating androgenic alopecia, but it does not provide results or conclusions from any study.

In this study, researchers evaluated CS12192, a selective JAK3 inhibitor, in an alopecia areata mouse model and found it reversed hair growth inhibition comparably to baricitinib, with better safety and similar immune-modulating mechanisms.

This study used an in silico/in vitro approach to identify potential inhibitors of the enzyme SRD5A2, finding that the androgen receptor modulator MK-0773 is a moderate inhibitor, although it does not act as a covalent inhibitor like finasteride.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This study found that PNU 157706 is a highly potent inhibitor of human 5α-reductase enzymes, showing a stronger and longer-lasting antiprostatic effect in rats compared to finasteride.

This study found that Black patients with alopecia areata showed an average 20% reduction in scalp involvement after JAK inhibitor therapy, indicating positive treatment outcomes in this group.

This review examines the role of steroidal inhibitors in treating prostatic diseases but presents no new clinical results.

In this study, PEVIII, a nanocomposite chitosan-coated vesicle containing both α-hederin and hederacoside C, demonstrated notable antibacterial activity against Pseudomonas aeruginosa in a keratitis model, showing significant lesion reduction, tissue improvement, and decreased bacterial load and inflammatory markers compared to other treatments.

This review highlights that JAK inhibitors have transformed severe alopecia areata treatment by disrupting disease signaling, emphasizing the need for strategies to address non-responders and manage treatment discontinuation.

This study describes that 65% of patients receiving imatinib mesylate in a patient assistance program experienced skin hypopigmentation, primarily in ethnically Chinese individuals, suggesting variability across populations.

This review discusses the pharmacological properties and therapeutic potential of K+ channel opening compounds, noting their prospective use in treating cardiovascular and respiratory conditions, but reports no new results.

This review discusses the potential of combined therapy with WP 631 and epothilone B for ovarian cancer, but reports no new clinical results.

This study found that rapamycin effectively inhibits TPA-induced keratinocyte proliferation and skin tumor promotion by targeting mTORC1 signaling in both wild-type and transgenic mice.

This study found that small molecule AP-1 inhibitors may selectively target SMO inhibitor-resistant basal cell carcinoma cells characterized by specific markers, potentially enhancing combinatorial cancer therapies.

In this study, researchers using network pharmacology and molecular docking methods found that compounds from Avicennia Marina could inhibit hepatitis C virus infection by targeting key proteins such as AKT1 and TNF-α, showing potential for anti-HCV treatments.

This study found that short-term treatment with ROCKi significantly increased keratinocyte stem cell proliferation without affecting their stemness, suggesting a potential safe approach for improving in vitro keratinocyte cultures for clinical applications.

This study found that some synthesized heterocyclic derivatives showed promising 5α-reductase inhibitor, antiviral, and anti-tumor activities, surpassing several reference drugs in effectiveness.

This study observed that JAK inhibitor therapy may be safely administered to patients with alopecia areata and latent HBV or stable TB, without reactivation of these infections, when appropriate monitoring and prophylaxis are used.

Ritlecitinib may help treat alopecia areata by protecting hair follicles.

JAK inhibitors help regrow eyebrow and eyelash hair and improve anxiety and depression in some alopecia areata patients.

This study found that targeting mTORC1 with rapamycin effectively inhibited skin tumor promotion in a mouse model, highlighting a potential target for cancer chemoprevention.

This study found that platelet-rich plasma can transiently inhibit bacterial growth in vitro against multidrug-resistant strains from diabetic foot infections, although its efficacy diminished over time and did not affect biofilm formation.

This study found that minoxidil prevents long-term serotonergic toxicity induced by MDMA in rats, primarily by opening mitochondrial KATP channels and involving Akt and MAP kinases in its neuroprotective mechanism.

This study identified certain benzopyran derivatives with a bulky tert-butyloxycarbonylamino group as effective KATP channel openers that inhibit insulin secretion in rat pancreatic islets.